LU90155I2 - Vistide - cidofovir 75 mg/ml - Google Patents

Vistide - cidofovir 75 mg/ml

Info

Publication number
LU90155I2
LU90155I2 LU90155C LU90155C LU90155I2 LU 90155 I2 LU90155 I2 LU 90155I2 LU 90155 C LU90155 C LU 90155C LU 90155 C LU90155 C LU 90155C LU 90155 I2 LU90155 I2 LU 90155I2
Authority
LU
Luxembourg
Prior art keywords
derivatives
compounds
antiviral activity
vistide
cidofovir
Prior art date
Application number
LU90155C
Other languages
English (en)
Original Assignee
Ceskoslovenska Akademie Ved
Rega Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ceskoslovenska Akademie Ved, Rega Foundation filed Critical Ceskoslovenska Akademie Ved
Publication of LU90155I2 publication Critical patent/LU90155I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509—Six-membered rings
    • C07F9/6512—Six-membered rings having the nitrogen atoms in positions 1 and 3

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
LU90155C 1986-07-18 1997-10-21 Vistide - cidofovir 75 mg/ml LU90155I2 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CS865469A CS264222B1 (en) 1986-07-18 1986-07-18 N-phosphonylmethoxyalkylderivatives of bases of pytimidine and purine and method of use them

Publications (1)

Publication Number Publication Date
LU90155I2 true LU90155I2 (fr) 1997-12-22

Family

ID=5399635

Family Applications (1)

Application Number Title Priority Date Filing Date
LU90155C LU90155I2 (fr) 1986-07-18 1997-10-21 Vistide - cidofovir 75 mg/ml

Country Status (21)

Country Link
US (3) US5142051A (fr)
EP (1) EP0253412B1 (fr)
JP (1) JPH0822866B2 (fr)
KR (1) KR950004179B1 (fr)
AT (1) ATE57932T1 (fr)
AU (1) AU600002B2 (fr)
CA (1) CA1340856C (fr)
CS (1) CS264222B1 (fr)
DE (2) DE3765864D1 (fr)
DK (1) DK170646B1 (fr)
EG (1) EG18273A (fr)
ES (1) ES2036194T3 (fr)
FI (1) FI86856C (fr)
GR (1) GR3002534T3 (fr)
IE (1) IE60117B1 (fr)
IL (1) IL83235A (fr)
LU (1) LU90155I2 (fr)
NL (1) NL970036I2 (fr)
NZ (1) NZ221100A (fr)
PT (1) PT85354B (fr)
ZA (1) ZA875283B (fr)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CS264222B1 (en) * 1986-07-18 1989-06-13 Holy Antonin N-phosphonylmethoxyalkylderivatives of bases of pytimidine and purine and method of use them
US5650510A (en) * 1986-11-18 1997-07-22 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Antiviral phosphonomethoxyalkylene purine and pyrimidine derivatives
NZ222553A (en) * 1986-11-18 1991-07-26 Bristol Myers Co Phosphonomethoxyalkylene purine and pyrimidine derivatives and pharmaceutical compositions
JPH0217199A (ja) * 1988-07-05 1990-01-22 Japan Tobacco Inc ２’−デオキシ−β−アデノシンの製造方法
US5688778A (en) * 1989-05-15 1997-11-18 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Nucleoside analogs
EP0452935B1 (fr) * 1990-04-20 1995-06-21 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic (Phosphonométhoxy)-2-propyl-guanines chirales comme agents anti-viraux
US5302585A (en) * 1990-04-20 1994-04-12 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Use of chiral 2-(phosphonomethoxy)propyl guanines as antiviral agents
CZ285420B6 (cs) * 1990-04-24 1999-08-11 Ústav Organické Chemie A Biochemie Avčr N-(3-Fluor-2-fosfonylmethoxypropyl)deriváty purinových a pyrimidinových heterocyklických bazí, způsoby jejich přípravy a použití
CS276072B6 (en) * 1990-08-06 1992-03-18 Ustav Organicke Chemie A Bioch (2R)-2-/DI(2-PROPYL)PHOSPHONYLMETHOXY/-3-p-TOLUENESULFONYLOXY -1- TRIMETHYLACETOXYPROPANE AND PROCESS FOR PREPARING THEREOF
DE69132276T2 (de) * 1990-08-10 2001-03-01 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic, Prag/Praha Verfahren zur herstellung von nukleotiden
DE69129650T2 (de) * 1990-09-14 1999-03-25 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic, Prag/Praha Wirkstoffvorläufer von Phosphonaten
US5208221A (en) * 1990-11-29 1993-05-04 Bristol-Myers Squibb Company Antiviral (phosphonomethoxy) methoxy purine/pyrimidine derivatives
JP3497505B2 (ja) * 1991-10-11 2004-02-16 インスティテュート オブ オルガニック ケミストリー アンド バイオケミストリー オブ ザ アカデミー オブ サイエンシズ オブ ザ チェコ パブリック 抗ウイルス性非環式ホスホノメトキシアルキル置換アルケニル及びアルキニルプリン及びピリミジン誘導体
US6057305A (en) * 1992-08-05 2000-05-02 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Antiretroviral enantiomeric nucleotide analogs
US5817647A (en) * 1993-04-01 1998-10-06 Merrell Pharmaceuticals Inc. Unsaturated acetylene phosphonate derivatives of purines
US5514798A (en) * 1993-06-02 1996-05-07 Gilead Sciences, Inc. Method and cyclic carbonates for nucleotide analogues
KR100386685B1 (ko) * 1993-09-17 2003-12-31 길리애드 사이언시즈, 인코포레이티드 뉴클레오타이드동족체류
US5798340A (en) 1993-09-17 1998-08-25 Gilead Sciences, Inc. Nucleotide analogs
US5656745A (en) * 1993-09-17 1997-08-12 Gilead Sciences, Inc. Nucleotide analogs
US5502177A (en) * 1993-09-17 1996-03-26 Gilead Sciences, Inc. Pyrimidine derivatives for labeled binding partners
US5468752A (en) * 1994-04-04 1995-11-21 Freeman; William R. Treatment of conditions of abnormally increased intraocular pressure by administration of HPMPC and related phosphonylmethoxyalkylcytosines
EP0754046A1 (fr) * 1994-04-04 1997-01-22 FREEMAN, William R. Emploi de nucleosides de phosphonylemethoxyalkyle pour traiter la pression intra-oculaire elevee
US5977061A (en) * 1995-04-21 1999-11-02 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic N6 - substituted nucleotide analagues and their use
US5717095A (en) * 1995-12-29 1998-02-10 Gilead Sciences, Inc. Nucleotide analogs
US6093816A (en) 1996-06-27 2000-07-25 Isis Pharmaceuticals, Inc. Cationic lipids
US5922695A (en) 1996-07-26 1999-07-13 Gilead Sciences, Inc. Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
DK1256584T3 (da) * 1997-07-25 2004-12-06 Gilead Sciences Inc Fremgangsmåde til fremstilling af adefovir-dipivoxil
ES2237189T3 (es) 1998-11-02 2005-07-16 Gilead Sciences, Inc. Terapia de combinacion para tratar virus de la hepatitis b.
US6407077B1 (en) 1998-11-05 2002-06-18 Emory University β-L nucleosides for the treatment of HIV infection
US7205404B1 (en) * 1999-03-05 2007-04-17 Metabasis Therapeutics, Inc. Phosphorus-containing prodrugs
US20030187261A1 (en) * 2000-01-07 2003-10-02 Libor Havlicek Purine derivatives, process for their preparation and use thereof
AUPQ806700A0 (en) * 2000-06-08 2000-07-06 Commonwealth Scientific And Industrial Research Organisation Antiviral agents
OA12393A (en) 2000-07-21 2006-04-18 Gilead Sciences Inc Prodrugs of phosphonate nucleotide analogues and methods for selecting and making same.
CN1503796B (zh) 2001-03-01 2012-07-04 三角药品公司 顺-ftc的多晶型物及其它晶型
CZ297267B6 (cs) * 2001-06-29 2006-10-11 Ústav organické chemie a biochemie AV CR Deriváty pyrimidinu nesoucí fosfonátovou skupinu,zpusob jejich prípravy, jejich pouzití pro lécbu a farmaceutické prípravky tyto látky obsahující
US7247621B2 (en) * 2002-04-30 2007-07-24 Valeant Research & Development Antiviral phosphonate compounds and methods therefor
AU2003235501A1 (en) 2002-05-13 2003-11-11 Metabasis Therapeutics, Inc. PMEA and PMPA cyclic producing synthesis
US7214668B2 (en) * 2002-05-13 2007-05-08 Metabasis Therapeutics, Inc. Phosphonic acid based prodrugs of PMEA and its analogues
SI1583542T1 (sl) * 2003-01-14 2008-12-31 Gilead Sciences Inc Sestavki in postopki za kombinacijsko antivirusnoterapijo
EP1644389B1 (fr) 2003-06-16 2011-01-19 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Composes de pyrimidine avec des groupes phosphonate, en tant qu'analogues nucleotidiques antiviraux
US20050080053A1 (en) * 2003-08-29 2005-04-14 Biocryst Pharmaceuticals, Inc. Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases
EP1686949A2 (fr) * 2003-11-24 2006-08-09 Viropharma Incorporated Composes, compositions et procedes pour le traitement et la prophylaxie d'infections de l'hepatite c virale et de maladies associees
WO2005090370A1 (fr) 2004-02-05 2005-09-29 The Regents Of The University Of California Agents pharmacologiquement actifs contenant des phosphonates esterifies, et leurs procedes d'utilisation
WO2005107742A1 (fr) 2004-05-05 2005-11-17 Yale University Nouveaux analogues antiviraux de l'helioxanthine
CN1964967B (zh) * 2004-06-08 2014-04-16 症变治疗公司 路易斯酸介导的环状酯的合成
EP1831235B1 (fr) 2004-12-16 2013-02-20 The Regents of The University of California Medicaments destines au poumon
WO2006130217A2 (fr) * 2005-04-01 2006-12-07 The Regents Of The University Of California Esters de phosphate de phosphonates de nucleosides substitues
JP2008535862A (ja) 2005-04-08 2008-09-04 キメリクス，インコーポレイテッド ポックスウイルス感染の治療のための化合物、組成物および方法
EP1865967A4 (fr) * 2005-04-08 2011-02-09 Chimerix Inc Composes, compositions et methodes de traitement d'infections virales et autres troubles medicaux
TWI375560B (en) * 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
CN100526315C (zh) 2005-06-16 2009-08-12 浙江医药股份有限公司新昌制药厂 N2-喹啉或异喹啉取代的嘌呤衍生物及其制备方法和其用途
KR101294467B1 (ko) * 2005-07-25 2013-09-09 인터뮨, 인크. Ｃ형 간염 바이러스 복제의 신규 거대고리형 억제제
BRPI0617274A2 (pt) * 2005-10-11 2011-07-19 Intermune Inc compostos e métodos para a inibição de replicação viral de hepatite c
US8076303B2 (en) 2005-12-13 2011-12-13 Spring Bank Pharmaceuticals, Inc. Nucleotide and oligonucleotide prodrugs
FR2908133B1 (fr) * 2006-11-08 2012-12-14 Centre Nat Rech Scient Nouveaux analogues de nucleotides comme molecules precurseurs d'antiviraux
GB0709408D0 (en) * 2007-05-16 2007-06-27 Katholleke Universiteit Leuven Anti-col herpes virus compounds
US20090181931A1 (en) * 2008-01-16 2009-07-16 Oncolys Biopharma, Inc. Antiviral activity of cidofovir against oncolytic viruses
AU2009206673B2 (en) 2008-01-25 2015-04-23 Chimerix, Inc. Methods of treating viral infections
TWI444384B (zh) 2008-02-20 2014-07-11 Gilead Sciences Inc 核苷酸類似物及其在治療惡性腫瘤上的用途
US20110059921A1 (en) * 2008-03-27 2011-03-10 Ektar Therapeutics Oligomer-Nitrogenous Base Conjugates
MX2010011306A (es) * 2008-04-15 2010-11-09 Intermune Inc Nuevos inhibidores macrociclicos de la replicacion del virus de la hepatitis c.
CN102216321A (zh) * 2008-10-15 2011-10-12 因特蒙公司 治疗性抗病毒肽
US8614200B2 (en) 2009-07-21 2013-12-24 Chimerix, Inc. Compounds, compositions and methods for treating ocular conditions
WO2011017253A1 (fr) 2009-08-03 2011-02-10 Chimerix, Inc. Composition et méthodes de traitement des infections virales et des tumeurs d'origine virale
WO2011041551A1 (fr) * 2009-10-01 2011-04-07 Intermune, Inc. Peptides antiviraux thérapeutiques
EP3216789A1 (fr) 2010-02-12 2017-09-13 Chimerix, Inc. Procédés de traitement d'une infection virale
EP2371369A1 (fr) 2010-04-01 2011-10-05 Institut Gustave Roussy (IGR) Inhibiteur EGFR et agent antiviral pour une utilisation simultanée, séparée ou séquentielle pour le traitement, la prévention et/ou la palliation du cancer
CA2797601A1 (fr) 2010-04-26 2011-11-10 Chimerix, Inc. Methodes de traitement d'infections retrovirales et regimes posologiques associes
BR112013014485B1 (pt) 2010-12-10 2021-03-30 Sigmapharm Laboratories, Llc Composições farmacêuticas compreendendo pró-fármacos análogos de nucleotídeos de fosfonato ativos por via oral e sistema de embalagem de recipiente/fechamento contendo as ditas composições
EP2667874A4 (fr) * 2011-01-27 2014-07-30 Univ Princeton Inhibiteurs de kinase mtor en tant qu'agents antiviraux
WO2012138954A1 (fr) 2011-04-07 2012-10-11 Johnson Matthey Public Limited Company Formes de cidofovir
WO2013095684A1 (fr) 2011-12-22 2013-06-27 Geron Corporation Analogues de guanine en tant que substrats de télomérase et affecteurs de la longueur de télomères
EP2846788A1 (fr) 2012-05-11 2015-03-18 Akron Molecules AG Utilisation de composés pour le traitement de la douleur
WO2014068265A1 (fr) 2012-10-29 2014-05-08 Cipla Limited Analogues de phosphonate antiviraux et leur procédé de préparation
CN107056838A (zh) 2013-03-15 2017-08-18 加利福尼亚大学董事会 无环核苷膦酸二酯
AU2015217221A1 (en) 2014-02-13 2016-08-11 Ligand Pharmaceuticals, Inc. Prodrug compounds and their uses
JP2017520545A (ja) 2014-07-02 2017-07-27 リガンド・ファーマシューティカルズ・インコーポレイテッド プロドラッグ化合物およびそれらの使用
SG11201701957XA (en) 2014-09-15 2017-04-27 Univ California Nucleotide analogs
WO2017048956A1 (fr) 2015-09-15 2017-03-23 The Regents Of The University Of California Analogues nucléotidiques
JP6860585B2 (ja) 2016-03-09 2021-04-14 ヤンセン バイオファーマ インク． 非環状抗ウイルス 優先出願の参照による組み込み
CA3087932A1 (fr) 2018-01-09 2019-07-18 Ligand Pharmaceuticals, Inc. Composes acetal et leurs utilisations therapeutiques
US12404332B2 (en) 2020-03-13 2025-09-02 Research Development Foundation Methods for diagnosing and treating cancers
US20230218644A1 (en) 2020-04-16 2023-07-13 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus
KR20250052378A (ko) 2022-07-21 2025-04-18 안티바 바이오사이언시즈, 인크. Hpv 감염 및 hpv-유도 신생물의 치료를 위한 조성물 및 투여 형태

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU521577B2 (en) * 1977-02-24 1982-04-22 Wellcome Foundation Limited, The 9-hydroxyethoxymethyl guanine phosphates
US4287188A (en) * 1977-02-24 1981-09-01 Burroughs Wellcome Co. Purine derivatives
DE2909709A1 (de) * 1979-03-12 1980-09-25 Kailash Kumar Dr Gauri Verfahren zur herstellung von nucleotidderivaten, neue nucleotidderivate und daraus hergestellte arzneimittel
ES8507550A1 (es) * 1982-09-30 1985-09-16 Syntex Inc Procedimiento para la preparacion de 1-esteres monofosfato, 1,3-bis-esteres fosfato y esteres fosfato ciclico de 9-(1,3-dihidroxi-2-propoximetil)-guanina
CS233665B1 (en) * 1983-01-06 1985-03-14 Antonin Holy Processing of isomere o-phosphonylmethylderivative of anantiomere racemic vicinal diene
DE3490262T1 (de) * 1983-05-24 1985-11-28 Sri International, Menlo Park, Calif. Antivirus-Mittel
US5047533A (en) * 1983-05-24 1991-09-10 Sri International Acyclic purine phosphonate nucleotide analogs
IL72173A0 (en) * 1983-06-24 1984-10-31 Merck & Co Inc Guanine derivatives,their preparation and pharmaceutical compositions containing them
US4670424A (en) * 1983-09-19 1987-06-02 Merck & Co., Inc. Cyclic pyrophosphates of purine and pyrimidine acyclonucleosides
US4590269A (en) * 1984-03-29 1986-05-20 Syntex (U.S.A.) Inc. Process for preparing the cyclic phosphate ester of substituted 9-(1,3-dihydroxy-2-propoxymethyl)purines
US4579849A (en) * 1984-04-06 1986-04-01 Merck & Co., Inc. N-alkylguanine acyclonucleosides as antiviral agents
CS263952B1 (en) * 1985-04-25 1989-05-12 Holy Antonin Remedy with antiviral effect
CS263951B1 (en) * 1985-04-25 1989-05-12 Antonin Holy 9-(phosponylmethoxyalkyl)adenines and method of their preparation
CS264222B1 (en) * 1986-07-18 1989-06-13 Holy Antonin N-phosphonylmethoxyalkylderivatives of bases of pytimidine and purine and method of use them
NZ222553A (en) * 1986-11-18 1991-07-26 Bristol Myers Co Phosphonomethoxyalkylene purine and pyrimidine derivatives and pharmaceutical compositions
CA1330794C (fr) * 1987-03-27 1994-07-19 Phillip Frost Composes antiviraux, formes et methodes pharmaceutiques

Also Published As

Publication number Publication date
DK373487D0 (da) 1987-07-17
FI86856B (fi) 1992-07-15
IL83235A (en) 1992-11-15
ATE57932T1 (de) 1990-11-15
EG18273A (en) 1992-12-30
NL970036I2 (nl) 1998-03-02
IE60117B1 (en) 1994-06-01
PT85354B (pt) 1990-04-30
DK170646B1 (da) 1995-11-20
EP0253412A3 (en) 1989-04-26
JPH0822866B2 (ja) 1996-03-06
DE3765864D1 (de) 1990-12-06
KR880001688A (ko) 1988-04-26
CS546986A1 (en) 1988-08-16
IL83235A0 (en) 1987-12-31
PT85354A (en) 1987-08-01
NZ221100A (en) 1991-09-25
IE871944L (en) 1988-01-18
EP0253412A2 (fr) 1988-01-20
NL970036I1 (nl) 1997-12-01
US5641763A (en) 1997-06-24
FI86856C (fi) 1992-10-26
FI873165L (fi) 1988-01-19
AU7575987A (en) 1988-01-21
US5869467A (en) 1999-02-09
AU600002B2 (en) 1990-08-02
GR3002534T3 (en) 1993-01-25
DK373487A (da) 1988-01-19
CA1340856C (fr) 1999-12-21
FI873165A0 (fi) 1987-07-17
US5142051A (en) 1992-08-25
ZA875283B (en) 1988-03-30
JPS6345289A (ja) 1988-02-26
CS264222B1 (en) 1989-06-13
DE19775085I2 (de) 2004-01-15
KR950004179B1 (en) 1995-04-27
ES2036194T3 (es) 1993-05-16
EP0253412B1 (fr) 1990-10-31

Similar Documents

Publication Publication Date Title
LU90155I2 (fr) Vistide - cidofovir 75 mg/ml
IL81002A (en) 3,4-diphenyl-pyrazoline-1-carboxamide derivatives,processes for the preparation thereof and insecticidal and acaricidal compositions containing the same
DK529888D0 (da) Substituerede n-(1-alkyl-3-hydroxy-4-piperidinyl) benzamider
ATE89547T1 (de) Dopamin-vorlaeufer.
IT1228288B (it) Composti ad attivita' antiserotoninica
SE8404065D0 (sv) Novel biologically active compounds
IT1224405B (it) Composti attivi sul sistema cardiovascolare
SE8600658D0 (sv) Novel composition of matter
IT1216104B (it) Peptidi ad attivita' farmaceutica.
DE3778642D1 (de) Therapeutikum zur behandlung von magengeschwueren.
ATE106883T1 (de) Azelastin-embonat, verfahren zu seiner herstellung und pharmazeutische zubereitungen, die als wirkstoff azelastin-embonat enthalten.
ATE93524T1 (de) Mitomycinanaloge, verfahren zu ihrer herstellung und pharmazeutische zubereitungen.
IT1216103B (it) Peptidi ad attivita' farmaceutica.
IT1224404B (it) Composti attivi sul sistema cardiovascolare
IT8720229A0 (it) Composizioni farmaceutiche adattivita' spasmolitica contenente come principio attio idanpramina
SE8704049D0 (sv) Novel pharmacological compounds